 Delcath Systems, Inc. DCTH, an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that the Companys Board of Directors has authorized a 1-for-700 reverse stock split of the Companys common stock. Stockholders authorized the Companys Board of Directors to effect the reverse stock split at the annual meeting of stockholders on September 17, 2019. The reverse stock split will be effected prior to the initiation of trading on December 24, 2019. 